ClinicalTrials.gg
RecruitingNCT02203903RESOLVEUpdated Aug 14, 2026

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

A Phase 1 interventional study of Tumor associated antigen lymphocytes (TAA-T) in Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, sponsored by Catherine Bollard. Recruiting at 2 sites in United States. Open to participants aged 6 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Primary conditionHematologic NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hematologic Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Hematologic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Catherine Bollard · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2015; still recruiting 11 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
6 Months to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
271st of 660
50 · median 40
Started
2015
with 38 others
Phase 1
197 of 823
37 open now
Primary completion
2026-11
later than 72 of 274 live
Registered
292nd of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 271st largest by planned enrollment of the 660 interventional ones that give a count, is one of 39 that started in 2015, is one of 197 in phase 1, reaches primary completion later than 72 of the 274 other live ones, and was the 292nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 6 Months to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.

Read the detailed description

Patients with evidence of high-risk or relapsed or persistent hematopoietic malignancies (for example but not limited to: acute myeloid leukemia and myelodysplastic syndrome (MDS)) will be eligible for this study.

Patients with high risk for relapse will be eligible to receive planned infusion of allogeneic TAA-T after HSCT (with high risk AML and MDS who have undergone allo-HSCT and are in a hematologic remission).

We will utilize our established protocol for the manufacture of tumor multi-antigen associated specific cytotoxic T lymphocytes. Peripheral blood mononuclear cells will be exposed to antigen presenting cells pulsed with peptides to tumor antigens (PRAME, WT1, Survivin) in a cytokine milieu favorable to T cell expansion/activation, inducing selective expansion of T cells targeted to kill tumor cells. Patients would be monitored for the development of toxicity. In patients with disease at the time of TAA-T infusion, efficacy would be evaluated as a secondary endpoint using standard criteria. Exploratory investigational analyses would include monitoring of cytokine and cellular milieu pre- and post- TAA-T infusion and in vitro characterization of the host tumor, donor lymphocyte product, and TAA-T product.

TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first at dose level 4 . Infusions will be within first 5 months post-HSCT.

Patients will receive a TAA-T cell dose of 4 x 107 cells/m2.

Each patient will receive at least one infusion according to the enrolled dose level, where the expected volume of infusion is 1 to 10 cc.

If patients with active disease (defined as MRD+ at the time of TAA-T infusion) do not have ≥ grade 3 toxicity that is possibly, probably, or definitely attributed to TAA-T infusion and fail to rapidly progress with disease requiring urgent therapy, patients may receive a subsequent TAA-T cell dose (infusion #2). A subsequent dose (infusion #2) will also be available for those patients who have stable disease or a mixed, partial, or complete response (including continued complete response) by the International Working Group (IWG) criteria (see section 4.2.1) at the evaluation after the first TAA-T infusion.

Patients who have received at least 2 infusions of TAA-T are eligible to receive up to 6 additional doses (infusion #3 to #8) of TAA-T at monthly intervals each of which will consist of the same cell number as their enrolled dose level. Patients will not be able to receive additional doses until the initial safety profile is completed at 28 days following the second infusion. Notably, these doses will be identical to the treated dose for this patient (i.e. no subsequent dose escalation). Patients would then receive additional doses starting greater than 28 days from second infusion and be treated at the same dose level as he/she has previously received.

03

Conditions studied

  • Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

Browse trials for

04

In context

Hematologic Neoplasms Reclassified

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

This study's planned enrollment of 50 is close to the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Catherine Bollard is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient Inclusion Criteria to Enter Protocol:

  • Aged 6 months to 80 years.
  • Anticipated myeloablative or non-myeloablative hematopoietic stem cell transplant.
  • Patients with high risk AML and MDS who have received or will receive an allo-HSCT and have not had hematologic relapse of disease.
  • /Lansky score of ≥ 50.
  • Agree to use measures during study protocol participation (when age appropriate).
  • Patient or parent/guardian capable of providing .
  • T cell chimerism > 94% if collected from recipient of allo-HSCT

Recipient Exclusion Criteria to Enter Protocol:

  • Patients with uncontrolled infections.
  • Current evidence of > grade 2 or bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis.
  • Pregnancy (female of ).

Recipient Inclusion Criteria for TAA-T Administration:

  • Patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease.
  • less than 0.5 mg/kg/day prednisone or equivalent in the context of no escalation of treatment within the preceding 2 weeks
  • Karnofsky/Lansky score of ≥ 50.
  • \< 2.5 mg/dL, /ALT \<5x , Serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher).
  • Pulse oximetry of > 90% on room air.
  • > 250/ µL (may be supported with Granulocyte colony-stimulating factor (GCSF)).
  • Agree to use contraceptive measures during study protocol participation (when age appropriate).
  • Patient or parent/guardian capable of providing informed consent.
  • > 50% or LVSF > 27% (performed within the last 6 months) if history of TBI >500 cGy for arm A and B.
  • Total chimerism > 50%; or if cancer cells preclude this, donor T cell chimerism > 50% (performed within the last 6 months).

Recipient Exclusion Criteria for TAA-T Administration:

  • Patients who received ATG, Campath, or other T cell monoclonal antibodies within 28 days prior to TAA-T infusion.
  • No therapies (under IND, not extensively studied in the current clinical context) within 28 days prior to TAA-T infusion.
  • Uncontrolled infections.
  • Active Bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis.
  • Active acute GVHD or chronic GVHD requiring escalation of treatment within preceding 2 weeks of any grade is exclusion for Arm C patients.
  • Pregnancy or lactating (female of childbearing potential).
  • Patients who have or will be receiving 2nd allogeneic HSCT

Donor Inclusion Criteria:

  • Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have undergone eligibility evaluation as per FDA regulations outlined in 21 CFR 1271 subpart C. If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for TAA-T generation provided that there are no new reasons for ineligibility since the transplant donor evaluation.
  • Aged 6 months to 80 years.
  • Donor or guardian of pediatric capable of providing informed consent.
  • Donor must have completed infectious Disease (ID) testing up to 7 days before or after the collection of blood from the donor (related or unrelated) for TAA-T manufacturing. The following tests will be performed:

    • HB Core antibody
    • HIV1/2 NAT
    • Syphilis (T. Pallidum IgG)
    • HTLV I/II
    • CMV total
    • HBV/ NAT
    • West Nile Virus NAT.
    • Cruz (Chagas) antibody
    • Hepatitis C
  • Female donors of childbearing age must have a negative pregnancy test within 7 days of blood collection for TAA-T manufacturing.

Donor Exclusion Criteria:

  • Donation of cells would pose a physical or psychological risk to the donor.
  • Female donors of childbearing age who are known to be pregnant.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Tumor associated antigen lymphocytes (TAA-T)

    TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT. Patients will receive a TAA-T cell dose of 4 x 107 cells/m2.

    Biological: Tumor associated antigen lymphocytes (TAA-T)

Interventions

07

What researchers measure

Primary outcomes

  1. Safety of investigational product (TAA-T)

    Acute GVHD grades III-IV within 45 days of the last dose of TAA-T

    Time frame: 45 days

  2. Safety of TAA-T cells

    Grades 3-5 infusion-related adverse events within 45 days of the last dose of TAA-T

    Time frame: 45 days

  3. Safety of TAA-Ts

    Grades 4-5 non-hematological attributable adverse events within 45 days of TAA-T dose and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0

    Time frame: 45 days

  4. Event-free survival

    To determine if event-free survival (EFS) at twelve months post-HSCT is improved with TAA-T administration for AML and MDS (Arm C).

    Time frame: Twelve months post-HSCT

Secondary outcomes

  1. Tumor associated antigen lymphocytes (TAA-T) responses

    To determine the number of patients who respond to tumor multi-antigen associated specific cytotoxic lymphocytes (TAA-T) for treatment for high risk or relapsed or refractory hematopoietic malignancies as defined by those who maintain or achieve CR, PR, MR or SD following TAA-T infusion and evaluate if this was associated with in vivo persistence of TAA-T

    Time frame: 2 years

Other outcomes

  1. The incidence and severity of acute and/or chronic GVHD

    To determine the incidence and severity of acute and/or chronic GVHD in patients treated with TAA-T and compare this to historical controls

    Time frame: 2 years

  2. Event free and overall survival

    Event free and overall survival at 1 year for patients enrolled under Arm C.

    Time frame: 1 year

  3. Characterize the cytokine and lymphocyte cellular milieu pre- and post-infusion of TAA-T

    To characterize the cytokine and lymphocyte cellular milieu pre- and post-infusion of TAAT in vivo.

    Time frame: 2 years

  4. Compare specificity to tumor antigens before and after TAA-T infusion

    To characterize the TAA-T generated prior to infusion in terms of specificity to tumor antigens and compare this with tumor antigens present on patient samples, evaluating for in vitro activity of TAA-T.

    Time frame: 2 years

  5. To evaluate the incidence of post-transplant complications after TAA-T infusion.

    To evaluate the incidence of other post-transplant complications such as engraftment, sinusoidal obstructive syndrome, neutropenia and significant infections during the period of monitoring after cellular infusion.

    Time frame: 45 days

08

Study locations

2 of 2 sites recruiting
  • Childrens National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Tania Jain, MD
    Baltimore, Maryland 21287, United States
    Recruiting
    • Tania Jain, MD · Contacttjain2@jhmi.edu
    • Tania Jain, MD · Principal investigator
09

References and documents

Publications

  • Kinoshita H, Cooke KR, Grant M, Stanojevic M, Cruz CR, Keller M, Fortiz MF, Hoq F, Lang H, Barrett AJ, Liang H, Tanna J, Zhang N, Shibli A, Datar A, Fulton K, Kukadiya D, Zhang A, Williams KM, Dave H, Dome JS, Jacobsohn D, Hanley PJ, Jones RJ, Bollard CM. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 2022 Apr 26;6(8):2520-2534. doi: 10.1182/bloodadvances.2021006831. PubMed 35244681 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2015 (actual). Primary completion is estimated for Nov 2026, 139 months after the start.

Of 64 non-industry phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 88. This study's planned 139 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2014
First posted
Jul 30, 2014
StartActual
Apr 2, 2015
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jun 28, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02203903
Lead sponsor
Catherine Bollard
Responsible party
Catherine Bollard (Director- Center for Cancer and Immunology Research, Children's National Research Institute) — Sponsor-investigator
First posted
Jul 30, 2014
Start date
Apr 2, 2015
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 28, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Fahmida Hoq, MBBS, MS
Contact
fhoq@childrensnational.org
202-476-3634

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes

Start the discussion